PharmacoEconomics & Outcomes News

, Volume 832, Issue 1, pp 38–38 | Cite as

NICE decisions: July 2019

News item

The UK National Institute for Health and Care Excellence (NICE) published new or updated guidance on four treatments in July 2019.

Nusinersen for SMA

NICE has published amended draft guidance on nusinersen [Spinraza; Biogen] for the treatment of spinal muscular atrophy (SMA) in children, following a proposal for extending the terms of the managed access agreement (MAA) between NHS1 England and Biogen for funding the drug.1

The MAA will now include paediatric patients who have lost the ability to walk independently within the previous 12 months. Under the agreement of a revised deal between NHS England and Biogen, the NHS will fund nusinersen treatment for a time-limited period to allow further effectiveness data to be collected.

"Having considered new evidence about the effectiveness of Spinraza in people who have lost the ability to walk, NHS England and Biogen have been able to find a way forward that all parties are happy with and that will ensure Spinraza is available to as many...


  1. 1.
    NICE. Spinraza access agreement extended. Internet Document : 3 Jul 2019. Available from: URL:
  2. 2.
    NICE. Life-extending lung cancer treatment recommended for use on the NHS. Internet Document : 5 Jul 2019. Available from: URL:
  3. 3.
    Final appraisal document: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer. Internet Document : 5 Jul 2019. Available from: URL:
  4. 4.
    NICE. Device for preventing and relieving pain of cluster headaches approved by NICE in draft guidance. Internet Document : 5 Jul 2019. Available from: URL:

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations